OBJECTIVES: The objective of the study is the assessment of the economic impact of the adoption of a novel prognostic prostate cancer genomic test providing a clinical cell-cycle risk (CCR) score in the Greek healthcare system concerning localized low-risk prostate cancer.

METHODS: A budget impact model was developed using Microsoft Excel 2017 to estimate the costs of the novel prostate cancer test adoption in the Greek healthcare system for the low-risk prostate cancer patients versus not adoption. The model included population, clinical and cost parameters, which were extracted from the literature. In addition, an expert panel was recruited as was considered necessary to involve physicians to provide expertise inputs regarding the current Greek clinical practice and particularly for this risk group. Furthermore, a one-way sensitivity analysis via tornado diagram was constructed to assess the impact of parameter changes on the outputs.

RESULTS: In the base-case analysis, the genomic CCR score was the dominant strategy. Per-patient savings amount to 1.700€, with the total costs per patient and for 5 years found to be 5.200€ while current clinical practice costs estimated at 6.900€ . Total savings for all patients were calculated at 25 million € for the third payer while it should be noted that even in the first year of adoption the savings were found to be 5,5 million €. In addition, one-way sensitivity analysis demonstrated that the test was cost-saving.

CONCLUSIONS: The CCR score highlights a significant contribution to the improvement of the treatment of localized prostate cancer in Greece. It is therefore found that in addition to the clinical value through the personalized approach and the avoidance of the invasive procedure and related complications for the majority of patients in the low-risk group, this genomic test highlights an economic value for the payer which makes it an affordable technology for the country's health system.